Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083525
Status:
COMPLETED
Last Update Posted:
2008-01-24
First Post:
2004-05-25
Brief Title:
Urokinase-Plasminogen Activator uPA Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Sponsor:
Heidelberg Pharma AG
Organization:
Heidelberg Pharma AG
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety tolerability maximum tolerated dose MTD pharmacokinetics and pharmacodynamics of the combination of WX-UK1 and capecitabine in patients with advanced malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None